MannKind reports 2022 total revenues of $100M, up 32% YoY; Tyvaso DPI royalties $16M

MANNKIND CORP

2022-FY EPS reported -$0.34 revenue$99,770,000

Q4 2022 total revenues $36.1M (+188% YoY); full-year $99.8M (+32% vs 2021).
Afrezza net revenue $43.3M in 2022 (+11%); V-Go contributed $12.9M after Q2 acquisition.
Tyvaso DPI royalties $15.6M in 2022 ($9.1M in Q4); $37.9M manufacturing revenue deferred.
Cash and investments $172.8M at Dec 31, 2022; INHALE-1 pediatric trial 50% enrolled.
Inhaled clofazimine (MNKD-101) to enter adaptive Phase 2/3 study in H2 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.